Open AccessBrief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women
Author(s) -
Sally Hodder,
Kathleen Squires,
Cissy Kityo,
Debbie Hagins,
Anchalee Avihingsa,
Anna Kido,
Shuping Jiang,
Rohan Kulkarni,
Andrew Cheng,
Huyen Cao
Publication year - 2018
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000001663
Subject(s) - elvitegravir , cobicistat , tenofovir alafenamide , medicine , tolerability , emtricitabine , regimen , adverse effect , atazanavir , ritonavir , pharmacology , viral load , virology , human immunodeficiency virus (hiv) , antiretroviral therapy
The integrase inhibitor regimen [elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (TDF)] demonstrated superior efficacy when compared with a protease inhibitor regimen [ritonavir-boosted atazanavir (ATV + RTV) and FTC/TDF] in 575 treatment-naive women at week 48. We investigated the efficacy, safety, and tolerability of switching to a TAF-based, single-tablet regimen containing elvitegravir, cobicistat, FTC, and tenofovir alafenamide (E/C/F/TAF) versus remaining on ATV + RTV plus FTC/TDF.